Comments cbli vs psti advantage who??
CBLI Nuclear Radiation Treatment."partially funded the Russian Federation Ministry of Industry(“ MPT ”)". 3.7M FLOAT. Potential contracts w/Governments. Market cap really a joke vs The market for medical radiation countermeasures. Received Europe Orphan Drug Status For Acute Radiation Syndrome Treatment.
Company has much better balance sheet in 2017. expenses reduced about $12m in 2016 vs 2015. As of December 31, 2016, the Co. had $15.2m in cash.
from 10-K:
"We believe that entolimod is the most efficacious medical radiation countermeasure currently in development".
"Entolimod is a Toll-like receptor 5 (" TLR5 ") agonist, which we are developing as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (" ARS "), and as an oncology drug. We believe that entolimod is the most efficacious medical radiation countermeasure currently in development. Following is a summary of the clinical development of entolimod to date and regulatory status"
"The market for medical radiation countermeasures grew dramatically following the September 11, 2001 terrorist attacks and the subsequent use of anthrax in a biological attack in the U.S. Terrorist activities worldwide have continued in the intervening years and the possibility of chemical, biological, radiation and nuclear attacks continues to represent a perceived threat for governments world-wide. In addition to the U.S. government, which maintains a national stockpile of products for emergency use (the " National Stockpile "), we believe the potential markets for the sale of radiation countermeasures include U.S. federal, state and local governments, including defense and public health agencies; foreign governments; non-governmental organizations; multinational corporations; transportation and security companies; healthcare providers; and, nuclear power facilities"..
